Skip to main
  1. Stocks
  2. TriSalus Life Sciences Inc
  3. Forecast
TLSI

TLSI Stock Forecast & Price Target

TLSI Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

TriSalus Life Sciences is attractive because TriNav’s PEDD platform is showing commercial traction in a large, underpenetrated liver embolization market, where management estimates it has only about 10% share and 2025 revenue reached $45.2M, up 53% YoY. The company’s outlook is further supported by 2Q26 revenue of $11.4M, a 28% sequential rebound, reiterated FY26 guidance of $54M-$57M, and gross margin expansion to 86.8%, suggesting temporary sales-force disruption is giving way to operating leverage. Beyond liver, the pending TriNav Advance filing, adjacent indications such as UAE and thyroid, and a PEDD-enabled immunotherapy pipeline create multiple paths to expand the addressable market from roughly $480M toward the multibillion-dollar range.

Bears say

TriSalus Life Sciences is viewed negatively because its revenue base is still concentrated in TriNav, leaving the company highly exposed to slower-than-expected device adoption, limited physician awareness, and reimbursement that is revised annually. The recent commercial reset, including more than doubling the sales force, produced only limited productivity by the end of May 2026, while 1Q26 revenue fell 2.9% YoY to $8.9M and FY26 guidance was cut to $54M-$57M from $60M-$62M after the TriNav Advance FDA delay. Its longer-term thesis also carries meaningful execution risk: the PEDD evidence base remains largely retrospective and single-center, the bear case excludes the roughly $800M GAE opportunity, and the company is not yet profitable, raising dilution risk.

TLSI has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of TriSalus Life Sciences Inc and is not a guaranteed prediction by Public.com or investment advice.

TLSI Analyst Forecast & Price Prediction

Get the latest TLSI stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in TLSI

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About TriSalus Life Sciences Inc (TLSI) Forecast

Analysts have given TLSI a Strong Buy based on their latest research and market trends.

According to 3 analysts, TLSI has a Strong Buy consensus rating as of Oct 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

TriSalus Life Sciences Inc (TLSI)


TLSI Analyst Forecast & Price Prediction

Get the latest TLSI stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in TLSI

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover TLSI stock data and trends